摘要
有相当多的数据支持中枢胆碱能系统地在精神分裂症和情感障碍中起作用。目前在获得的增加毒蕈碱受体(CHRMs)结构性数据方面已经取得突破,了解他们在中枢神经系统功能和在合成药物中的作用,可以专门针对每个5-CHRMs。这意味着它适当的被认为是在精神分裂症和情绪障碍的病理生理学上的特定的角色。这篇综述集中对暗示CHRM1和CHRM4水平的改变的数据这篇综述将关注数据的表明CHRM1和CHRM4水平变化及牵连这些受体在精神分裂症的病理生理学数据,及表明CHRM2在情绪障碍作用的数据。会有一个对理解在CNS功能中的CHRM1,2和4的作用的最新进展及这些预测机制如何通过这些受体可以诱导在精神分裂症和情感障碍的普遍症状的选择基准。最后,将对以CHRM1和CHRM4治疗精神分裂症和CHRM2治疗抑郁症症状为靶标的潜在优势和存在问题的进行评论。
关键词: 乙酰胆碱,毒蕈碱受体,精神分裂症,抑郁狂躁型抑郁症,重度抑郁症,神经炎症
Current Molecular Medicine
Title:Possible Involvement of Muscarinic Receptors in Psychiatric Disorders: A Focus on Schizophrenia and Mood Disorders
Volume: 15 Issue: 3
Author(s): B. Dean and E. Scarr
Affiliation:
关键词: 乙酰胆碱,毒蕈碱受体,精神分裂症,抑郁狂躁型抑郁症,重度抑郁症,神经炎症
摘要: A considerable body of data supports a role for the central cholinergic system in the aetiologies of schizophrenia and mood disorders. There have been breakthroughs in gaining structural data on muscarinic receptors (CHRMs), understanding their role in CNS functioning and in synthesising drugs that can specifically target each of the 5 CHRMs. This means it is opportune to consider the role of specific CHRMs in the pathophysiologies of schizophrenia and mood disorders. This review will focus on data suggesting changes in levels of CHRM1 and CHRM4 implicate these receptors in the pathophysiology of schizophrenia whereas data suggest a role for CHRM2 in mood disorders. There will be a selected reference to recent developments in understanding the roles of CHRM1, 2 and 4 in CNS function and how these predict mechanisms by which these receptors could induce the symptoms prevalent in schizophrenia and mood disorders. Finally, there will be comments on the potential advantages and problems in targeting CHRM1 and CHRM4 to treat the symptoms of schizophrenia and CHRM2 to treat the symptom of depression.
Export Options
About this article
Cite this article as:
B. Dean and E. Scarr , Possible Involvement of Muscarinic Receptors in Psychiatric Disorders: A Focus on Schizophrenia and Mood Disorders, Current Molecular Medicine 2015; 15 (3) . https://dx.doi.org/10.2174/1566524015666150330144821
DOI https://dx.doi.org/10.2174/1566524015666150330144821 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Disrupted Structural Brain Network in AD and aMCI: A Finding of Long Fiber Degeneration
Current Alzheimer Research Cognitive Dysfunction in Depression – Pathophysiology and Novel Targets
CNS & Neurological Disorders - Drug Targets Commentary: Hot, Hotter, and Hottest Trends in α-Synuclein Research
Current Protein & Peptide Science Nanotherapeutics in Neuropathologies: Obstacles, Challenges and Recent Advancements in CNS Targeted Drug Delivery Systems
Current Neuropharmacology New Directions for Dementia
Current Neurovascular Research Ongoing In Vivo Studies with Cytoskeletal Drugs in Tau Transgenic Mice
Current Alzheimer Research Fine Tuning of Intracellular Ca<sup>2+</sup> Content by Pharmacological Agents – A Strategy to Prevent Synapse Loss in Alzheimer Disease Hippocampal Neurons
Current Alzheimer Research DYRK1A Kinase Inhibitors with Emphasis on Cancer
Mini-Reviews in Medicinal Chemistry Vascular Disease and Risk Factors in Chronic Kidney Disease
Vascular Disease Prevention (Discontinued) Past, Present and Future Therapeutics for Cerebellar Ataxias
Current Neuropharmacology Common Cellular and Molecular Mechanisms Underlying Alzheimer’s Disease and Type 2 Diabetes: A Knowledge-Driven Approach
CNS & Neurological Disorders - Drug Targets Neuroprotection by Association of Palmitoylethanolamide with Luteolin in Experimental Alzheimer’s Disease Models: The Control of Neuroinflammation
CNS & Neurological Disorders - Drug Targets Amyotrophic Lateral Sclerosis: From Research to Therapeutic Attempts and Therapeutic Perspectives
Current Medicinal Chemistry Pharmacological Treatment of Hypertension in Pregnancy
Current Pharmaceutical Design Protective Effects of Chronic Green Tea Consumption on Age-related Neurodegeneration
Current Pharmaceutical Design Mitochondria as Therapeutic Targets of Estrogen Action in the Central Nervous System
Current Drug Targets - CNS & Neurological Disorders Alkylglycerol Lipid Precursors: A Review of Therapeutic Strategies for Plasmalogen Replacement
Current Organic Chemistry Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets The Potential Role of Sirtuins Regarding the Effects of Exercise on Aging- Related Diseases
Current Aging Science The Role of Blood-Brain Barrier Transporters in Pathophysiology and Pharmacotherapy of Stroke
Current Pharmaceutical Design